All In Biotech

Drug Trial Radar · NCT07180160

Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer

Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: a Prospective, Randomised, Controlled, Multicentre Clinical Trial

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 123 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

123

Planned (sponsor's estimate)

Start

Sep 25, 2025

Primary completion

Sep 2027

Study completion Mar 2028

Sponsor

Lead sponsor
Wenjin YinAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.

Conditions

  • Advanced Breast Cancer

Interventions

  • QL1706Drug

    QL1706 is a single bifunctional MabPair product consisting of two engineered monoclonal antibodies (anti-PD-1 and anti-CTLA-4).

  • CDK4/6 inhibitorDrug

    palbociclib OR ribociclib OR abemaciclib OR dalpiciclib

  • FulvestrantDrug

    SERD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS)Time frame: From the date of starting study treatment to the date of first documentation of disease progression or death from any cause (up to approximately 1 year)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Renji Hospital, School of Medicine, Shanghai Jiaotong University

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.